CriticalAntidepressants. Other antidepressants of herbal origin×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
CYP2C19, CYP2C9 and CYP3A4 metabolise voriconazole in the liver, and inducers of these enzymes lower its blood levels (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). Hyperforin in St John's wort induces CYP3A4, CYP2B6, CYP2C9, CYP2C19 and the transporter P-glycoprotein in a dose-dependent way (St John's wort herbal monograph, EMA, sections 4.5 and 5.2). In a published study, healthy volunteers took St John's wort extract 300 mg three times daily for 15 days. Their mean voriconazole AUC after a single 400 mg dose then fell by 59%, while single doses of both taken together had no appreciable effect on it (voriconazole label, US Food and Drug Administration, FDA, section 12.3; voriconazole SmPC, EMA, section 4.5). Long-term use of St John's wort may therefore reduce voriconazole exposure (FDA voriconazole label, section 12.3). The Spanish St John's wort SmPC lists lower voriconazole levels with a risk of treatment failure (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).
Symptoms
The combination itself usually causes no symptoms: voriconazole blood levels fall and treatment may fail (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5; voriconazole label, US Food and Drug Administration, FDA, section 4). Voriconazole is used mainly for progressive, potentially life-threatening fungal infections and to prevent invasive fungal infections in high-risk recipients of an allogeneic haematopoietic stem cell transplant (voriconazole SmPC, European Medicines Agency, EMA, section 4.1). A weaker effect shows only as an infection that responds less well to treatment or as prophylaxis that fails.
Management
The combination is contraindicated: voriconazole must not be given with St John's wort, because St John's wort significantly lowers voriconazole levels (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.3 and 4.5; voriconazole label, US Food and Drug Administration, FDA, sections 4 and 7). The contraindication does not depend on the St John's wort dose. The Spanish St John's wort SmPC lists voriconazole among medicines that must not be taken with St John's wort (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The authorisation of that product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The EMA herbal monograph does not name voriconazole. It calls for special care with medicines whose metabolism depends on CYP3A4, CYP2C9 and CYP2C19. For traditional use products with a daily hyperforin intake of up to 1 mg, taken for no longer than 2 weeks, it reports no clinically relevant interactions (St John's wort herbal monograph, EMA, section 4.5). This exception does not change the contraindication in the voriconazole documents. The voriconazole documents do not say how long to wait between the last dose of St John's wort and the start of voriconazole. According to the monograph, increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (nº registro 79963), sección 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras (Arkopharma), nº registro 79963, revisión 11/2025 (texto de septiembre de 2016), secciones 4.3, 4.5 y 5.2; autorización suspendida desde el 11/06/2026, no hay otra ficha técnica de hipérico vigente en CIMA